Close Menu

This article has been update from a previous version to include comments made by Qiagen CEO Peer Schatz during the company's earnings call.

NEW YORK (GenomeWeb) – Qiagen said after the close of the market Thursday that its second quarter revenues grew 5 percent year over year as the company beat analysts' consensus estimate on the top and bottom lines.

For the three months ended June 30, Qiagen reported net sales of $334.4 million, exceeding the Wall Street estimate of $326.8 million. At constant exchange rates, Q2 revenues increased 6 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.